Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets - PubMed (original) (raw)
Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets
Kathrin Maedler et al. Diabetes. 2004 Jul.
Abstract
Increasing evidence indicates that a progressive decrease in the functional beta-cell mass is the hallmark of both type 1 and type 2 diabetes. The underlying causes, beta-cell apoptosis and impaired secretory function, seem to be partly mediated by macrophage production of interleukin (IL)-1beta and/or high-glucose-induced beta-cell production of IL-1beta. Treatment of type 1 and type 2 diabetic patients with the potassium channel opener diazoxide partially restores insulin secretion. Therefore, we studied the effect of diazoxide and of the novel potassium channel opener NN414, selective for the beta-cell potassium channel SUR1/Kir6.2, on glucose- and IL-1beta-induced apoptosis and impaired function in human beta-cells. Exposure of human islets for 4 days to 11.1 and 33.3 mmol/l glucose, 2 ng/ml IL-1beta, or 10 and 100 micromol/l of the sulfonylurea tolbutamide induced beta-cell apoptosis and impaired glucose-stimulated insulin secretion. The deleterious effects of glucose and IL-1beta were blocked by 200 micromol/l diazoxide as well as by 3 and 30 micromol/l NN414. By Western blotting with phosphospecific antibodies, glucose and IL-1beta were shown to activate the extracellular signal-regulated kinase (ERK) 1/2, an effect that was abrogated by 3 micromol/l NN414. Similarly, 1 micromol/l of the mitogen-activated protein kinase/ERK kinase 1/2 inhibitor PD098059 or 1 micromol/l of the l-type Ca(2+) channel blocker nimodipine prevented glucose- and IL-1beta-induced ERK activation, beta-cell apoptosis, and impaired function. Finally, islet release of IL-1beta in response to high glucose could be abrogated by nimodipine, NN414, or PD098059. Thus, in human islets, glucose- and IL-1beta-induced beta-cell secretory dysfunction and apoptosis are Ca(2+) influx and ERK dependent and can be prevented by the beta-cell selective potassium channel opener NN414.
Similar articles
- Potent and selective activation of the pancreatic beta-cell type K(ATP) channel by two novel diazoxide analogues.
Dabrowski M, Larsen T, Ashcroft FM, Bondo Hansen J, Wahl P. Dabrowski M, et al. Diabetologia. 2003 Oct;46(10):1375-82. doi: 10.1007/s00125-003-1198-1. Epub 2003 Sep 5. Diabetologia. 2003. PMID: 12961066 - Induction of beta-cell rest by a Kir6.2/SUR1-selective K(ATP)-channel opener preserves beta-cell insulin stores and insulin secretion in human islets cultured at high (11 mM) glucose.
Ritzel RA, Hansen JB, Veldhuis JD, Butler PC. Ritzel RA, et al. J Clin Endocrinol Metab. 2004 Feb;89(2):795-805. doi: 10.1210/jc.2003-031120. J Clin Endocrinol Metab. 2004. PMID: 14764798 - The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener, in healthy male subjects.
Zdravkovic M, Kruse M, Rost KL, Møss J, Kecskes A, Dyrberg T. Zdravkovic M, et al. J Clin Pharmacol. 2005 Jul;45(7):763-72. doi: 10.1177/0091270005276947. J Clin Pharmacol. 2005. PMID: 15951466 Clinical Trial. - Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives.
Hansen JB. Hansen JB. Curr Med Chem. 2006;13(4):361-76. doi: 10.2174/092986706775527947. Curr Med Chem. 2006. PMID: 16475928 Review. - Pancreatic and extrapancreatic sulfonylurea receptors.
Panten U, Schwanstecher M, Schwanstecher C. Panten U, et al. Horm Metab Res. 1992 Dec;24(12):549-54. doi: 10.1055/s-2007-1003387. Horm Metab Res. 1992. PMID: 1478610 Review.
Cited by
- Finnish diabetes risk score outperformed triglyceride-glucose index in diabetes risk prediction.
Nnamudi AC, Orhue NJ, Ijeh II, Nwabueze AN. Nnamudi AC, et al. J Diabetes Metab Disord. 2023 Jul 7;22(2):1337-1345. doi: 10.1007/s40200-023-01252-y. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975096 Free PMC article. - Growth arrest- and DNA-damage-inducible 45beta gene inhibits c-Jun N-terminal kinase and extracellular signal-regulated kinase and decreases IL-1beta-induced apoptosis in insulin-producing INS-1E cells.
Larsen CM, Døssing MG, Papa S, Franzoso G, Billestrup N, Mandrup-Poulsen T. Larsen CM, et al. Diabetologia. 2006 May;49(5):980-9. doi: 10.1007/s00125-006-0164-0. Epub 2006 Mar 10. Diabetologia. 2006. PMID: 16528573 - Type 2 diabetes, PUFAs, and vitamin D: their relation to inflammation.
Guadarrama-López AL, Valdés-Ramos R, Martínez-Carrillo BE. Guadarrama-López AL, et al. J Immunol Res. 2014;2014:860703. doi: 10.1155/2014/860703. Epub 2014 Feb 24. J Immunol Res. 2014. PMID: 24741627 Free PMC article. Review. - Ca2+ influx through L-type Ca2+ channels and Ca2+-induced Ca2+ release regulate cAMP accumulation and Epac1-dependent ERK 1/2 activation in INS-1 cells.
Pratt EP, Salyer AE, Guerra ML, Hockerman GH. Pratt EP, et al. Mol Cell Endocrinol. 2016 Jan 5;419:60-71. doi: 10.1016/j.mce.2015.09.034. Epub 2015 Oct 3. Mol Cell Endocrinol. 2016. PMID: 26435461 Free PMC article. - Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling.
Orellana JM, Kampe K, Schulze F, Sieber J, Jehle AW. Orellana JM, et al. Physiol Rep. 2017 May;5(10):e13287. doi: 10.14814/phy2.13287. Physiol Rep. 2017. PMID: 28554965 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous